Vertex to acquire endocrinology startup Crinetics for $10 billion, signaling push into new therapeutic areas

Vertex Pharmaceuticals announced a $10 billion cash purchase of Crinetics, an endocrinology-focused biotech.

The deal represents the largest acquisition in Vertex’s history and underscores its plan to expand beyond its cystic fibrosis franchise.

Industry observers see the transaction as a bid to broaden the company’s pipeline and climb toward the top tier of biopharma companies.